Processing

Please wait...

Settings

Settings

Goto Application

1. US20060292191 - Use of nanodispersions in pharmaceutical end formulations

Office
United States of America
Application Number 11446844
Application Date 05.06.2006
Publication Number 20060292191
Publication Date 28.12.2006
Grant Number 07871642
Grant Date 18.01.2011
Publication Kind B2
IPC
A61K 9/127
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
9Medicinal preparations characterised by special physical form
10Dispersions; Emulsions
127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 9/107
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
9Medicinal preparations characterised by special physical form
10Dispersions; Emulsions
107Emulsions
A61K 9/48
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
A61K 9/52
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
52Sustained or differential release type
A61K 9/66
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
52Sustained or differential release type
66containing emulsions, dispersions or solutions
Applicants Ciba Specialty Chemicals Corporation
Vesifact AG
Inventors Supersaxo Andreas Werner
Weder Hans Georg
Hüglin Dietmar
Röding Joachim Friedrich
Agents Loggins Shiela A.
Priority Data 98810422 11.05.1998 EP
Title
(EN) Use of nanodispersions in pharmaceutical end formulations
Abstract
(EN)

A nanodispersion comprises

  • (a) a membrane-forming molecule,
  • (b) a coemulsifier and
  • (c) a lipophilic component,
    in pharmaceutical end formulations, the nanodispersion being obtainable by
  • (α) mixing the components (a), (b) and (c) until a homogeneous clear liquid is obtained, and
  • (β) adding the liquid obtained in step (α) to the water phase of the pharmaceutical end formulations, where steps (α) and (β) may be carried out without high energy mixing or homogenization.

The nanodispersions prepared according to this invention are suitable as transport vehicles for pharmaceutical active agents.